Brain neoplasm

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

Researchers are testing an experimental oral drug called ND-003 in Chinese patients with advanced solid tumors that have worsened after standard treatment or have no standard options left. ND-003 blocks two proteins, NTRK and RET, that can drive cancer growth when altered. The ph…

Researchers are running a first-in-human Phase 1 trial of gamitrinib, an experimental drug that targets mitochondria in cancer cells, in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find the highest dose people …

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a drug called selumetinib in children and young adults with low grade glioma that has come back or not responded to other treatments. The drug works by blocking certain enzymes that help tumor cells grow. The goal is to find the best dose and see if it can shrink…

This early-phase trial tests whether a personalized vaccine made from each patient's tumor mutations, combined with Tumor Treating Fields (a device that sends electric fields to the brain), is safe and feasible for people with newly diagnosed glioblastoma. The 13 participants rec…

Researchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This phase III trial tests whether giving several small doses of radiation (fractionated radiosurgery) after removing a brain tumor is better than a single large dose. About 242 patients with cancer that spread to the brain will be randomly assigned to one of the two radiation pl…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This early-phase trial tests a new approach for people with HER2-positive brain tumors that have come back or not responded to standard treatment. Researchers take the patient's own T cells, attach a special antibody (anti-HER2) to them, and inject these 'CAR T cells' directly in…

This study tests a new way to give proton radiation to children with low-grade glioma, a common brain tumor. The goal is to avoid the hippocampus, a brain area key for memory, to reduce long-term memory loss. About 74 children will receive this targeted radiation, and researchers…

This phase 1 trial tests a peptide vaccine designed to target a specific mutation (H3K27M) found in certain aggressive brain tumors called diffuse midline gliomas. Fifteen newly diagnosed patients receive the vaccine along with the immunotherapy drug atezolizumab after standard r…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a combination of a vaccine targeting the CMV virus (PEP-CMV) and an immunotherapy drug (nivolumab) in children and young adults with certain aggressive brain tumors, including diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This phase III trial tests whether giving focused radiation (stereotactic radiosurgery) before surgery is better than after surgery for people with 1 to 4 brain metastases. About 237 participants will be randomly assigned to one of the two sequences. The goal is to see which orde…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This early study tests a combination approach for recurrent glioblastoma, an aggressive brain cancer. The treatment uses focused ultrasound (NaviFUS) to temporarily open the blood-brain barrier, allowing the drug Avastin (bevacizumab) to reach the tumor more effectively. Ten adul…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This phase 2 trial tests whether pembrolizumab, an immunotherapy drug, can help the immune system attack recurrent glioblastoma, an aggressive brain cancer that has come back. Researchers will give the drug to about 18 patients who need surgery for their tumor, and then study how…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This pilot study is testing a two-step treatment for people whose gliomas (a type of brain tumor) have come back after standard therapy. First, doctors use a laser guided by MRI to destroy as much tumor as possible. Then, they give a short course of focused radiation. The main go…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. …

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This study tests a higher dose of a precise type of radiation called proton therapy for people with aggressive meningiomas (brain tumors). The goal is to find a safe dose that can better control the tumor after surgery. The study includes 21 participants with either grade II or g…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if adding vorinostat could make the tumor cells more sensitive to chemot…

This early-stage study tests an experimental pill called CRN04894 in 18 adults with Cushing's syndrome caused by too much ACTH hormone. The drug works by blocking the receptor that ACTH acts on, aiming to lower cortisol levels and control the disease. The main goals are to check …

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This Phase I trial tests whether infusing specially trained immune cells, called TAA-T, can safely target and attack high-risk brain tumors in children and adults. The cells are made from the patient's own blood and are designed to recognize multiple tumor-related proteins, poten…

This study compares a targeted drug called selumetinib to standard chemotherapy (carboplatin/vincristine) in children aged 2 to 21 with neurofibromatosis type 1 (NF1) and low-grade glioma, a type of brain tumor. The goal is to see if selumetinib works as well or better at control…

This trial tests whether an experimental virus called C134 is safe when injected directly into the brain tumor in people with recurrent malignant glioma, including glioblastoma. Participants receive two doses of the virus during surgery to remove the tumor. The study focuses on s…

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This study tests whether a precise type of radiation called stereotactic radiosurgery, given after surgery to remove brain tumors, can prevent the tumors from coming back. About 132 patients with up to 3 brain metastases will be randomly assigned to receive either the radiation o…

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This trial is testing whether mebendazole, a drug commonly used to treat intestinal parasites, can help children with brain tumors called gliomas. The study combines mebendazole with standard chemotherapy drugs to see if it is safe and effective. It includes children and young ad…

This study looks at whether removing brain tumors with surgery after chemotherapy or radiation, but before the tumor grows back, is safe and helpful. About 40 adults with remaining tumor after prior treatment will be followed to see how they do compared to those who have surgery …

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This trial tests the drug savolitinib in children and adults whose brain tumors (medulloblastoma, high-grade glioma, or DIPG) have come back or not responded to treatment. The drug works by blocking an enzyme that some tumor cells need to grow. The study aims to find the safest d…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This Phase 2 trial tests a new approach for children whose medulloblastoma or ependymoma has come back. It combines a radioactive antibody (omburtamab) delivered directly into the brain's fluid spaces with standard chemotherapy drugs. The goal is to see if this combination can he…

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…

This phase 2 trial tests the drug pembrolizumab in 101 adults with cancer that has spread to the brain or spinal cord. The goal is to see if the drug can shrink or stabilize these tumors. Participants receive pembrolizumab along with standard imaging and sometimes radiation. The …

This phase 3 trial tests whether cabergoline, a drug already used for hormone-producing pituitary tumors, can shrink or slow the growth of non-functioning pituitary adenomas (NFPAs). These tumors do not produce excess hormones, so current treatment is limited to surgery or radiat…

This early-phase trial tests a new drug that targets a specific gene (EphA2) to slow tumor growth in people with advanced solid tumors that have spread or returned. About 49 participants will receive the drug to find the safest dose and check for side effects. The goal is to cont…

This early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a sa…

This trial tests whether giving a low-dose infusion of desmopressin (dDAVP) during surgery for complex brain tumors around the pituitary gland can prevent dangerously high sodium levels (hypernatremia) in the first 24 hours after surgery. High sodium can cause brain bleeding, sei…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This phase 2 trial is testing whether giving lower doses of radiation and chemotherapy can effectively treat a specific type of brain tumor called WNT-driven medulloblastoma in children and young adults aged 3 to 21. The goal is to kill cancer cells while reducing long-term side …

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This study tests whether using highly focused radiation on each individual brain tumor, instead of radiating the whole brain, can control cancer spread while protecting memory and thinking. It enrolls people with small cell lung cancer who have 1 to 10 brain metastases. Researche…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This trial tests a long-acting injection of leuprolide acetate in children with central precocious puberty, a condition where puberty starts too early. The goal is to suppress puberty-related hormones, slowing or stopping early development. The study includes children aged 4 to 9…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This pilot study tests an experimental device called Optune in people with recurrent atypical or anaplastic meningioma, a type of brain cancer that has come back after surgery or radiation. The device delivers electric fields to the tumor area to try to stop cancer cells from gro…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This trial tests whether a new type of MRI, called MR fingerprinting, can better show where a glioblastoma (an aggressive brain tumor) has spread compared to standard MRI. The goal is to help surgeons remove more of the tumor safely. The study involves adults with suspected gliob…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…

This Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This early-stage trial tests a vaccine called PEP-CMV in 30 children and young adults (ages 3–35) whose medulloblastoma or malignant glioma has come back. The vaccine is designed to train the immune system to attack tumor cells that carry a common virus protein (CMV). Participant…

This study tests a newer form of radiation called intensity-modulated proton therapy in children and young adults with craniopharyngioma, a rare brain tumor. The goal is to see if this precise radiation can better control the tumor while causing fewer side effects than older radi…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. It involves 46 adults with cancer that has spread to the brain. The goal is to improve tumor control without causing serious side e…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…

This study tests whether giving pregabalin before brain tumor surgery can safely reduce pressure inside the skull. One hundred adults will receive either pregabalin or a placebo before and on the morning of surgery. Researchers will measure pressure using a painless eye ultrasoun…

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if …

This study tests whether placing tiny radioactive seeds (Cs-131) in the brain during surgery can stop recurrent brain tumors from growing back. About 103 adults with previously treated brain metastases will be randomly assigned to receive either surgery alone or surgery plus this…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific gene…

This early-stage study tests whether adding a drug called acetazolamide to standard chemotherapy (temozolomide) is safe for people with a newly diagnosed, aggressive brain cancer (glioblastoma). Ten adults will take both drugs daily for 21-day cycles. The main goal is to find any…

This early-phase study tests a vaccine called SurVaxM in 35 children with certain brain tumors that have come back or are hard to treat. The vaccine is designed to teach the immune system to find and destroy tumor cells that have a protein called survivin. The goal is to see if i…

This early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receiv…

This early-phase trial tests whether delivering the cancer drug bevacizumab (Avastin) directly into the brain's arteries can safely treat vestibular schwannoma (acoustic neuroma), a non-cancerous tumor that can cause hearing loss. The study enrolls up to 30 adults with growing tu…

This early-stage trial tests a new surgical approach for recurrent glioblastoma, an aggressive brain cancer. After standard tumor removal, surgeons place a piece of abdominal tissue (omentum) into the brain cavity to bypass the blood-brain barrier. The study involves 10 adults an…

This study tests whether giving three rounds of very strong chemotherapy with stem cell rescue works better than one round for children under 10 with high-risk brain tumors. The goal is to improve survival without adding too many side effects. About 250 children will take part.

This study tests the Optune device, a wearable cap that creates low-intensity electric fields to disrupt cancer cell growth, in children with aggressive brain tumors. One group of children with recurrent high-grade glioma or ependymoma will use the device alone to see if it's fea…

This pilot study tests meclofenamate, a drug once used for pain, in 30 patients with brain metastases that have come back or grown despite prior treatments. The goal is to see if the drug can prevent new brain metastases and whether a larger trial is feasible. Researchers will mo…

This trial looks at the best time to give radiotherapy for brain metastases that can be surgically removed. It compares giving radiation before surgery, during surgery, or after surgery. The goal is to see which timing best prevents the tumor from coming back. About 90 adults wit…

This early-phase trial is testing two oral drugs, Sapanisertib and Telaglenastat, in 22 people with advanced non-small cell lung cancer that has spread to the brain or other organs. The drugs work by blocking key enzymes that cancer cells need to grow. The main goal is to find th…

This study tests whether adding cabergoline to osilodrostat works better than osilodrostat alone for controlling Cushing's disease. About 50 adults with active Cushing's disease will receive either the combination or the single drug. The goal is to see if the combo can lower cort…

This clinical trial tests a risk-adapted approach for young children with newly diagnosed brain tumors. The treatment starts with chemotherapy to delay radiation, giving the brain more time to develop. Then, radiation is carefully targeted to the tumor area to reduce side effects…

This study is for people with advanced non-small cell lung cancer that has spread to the brain. It tests whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to radiation therapy can better control the cancer. The goal is to find the safest and most effective…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to standard radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive different doses of MM…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests a new approach for people with aggressive brain tumors that have come back. Doctors place genetically modified neural stem cells directly into the tumor to make it more sensitive to the chemotherapy drug irinotecan. The study involves 18 participants …

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase II trial tests a drug called sacituzumab govitecan in 44 patients with HER2-negative breast cancer that has spread to the brain. The drug is a targeted antibody that delivers chemotherapy directly to cancer cells. The goal is to see if it can shrink brain tumors or slo…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests the drug trametinib in children and young adults (ages 1 month to 25 years) with low-grade glioma or plexiform neurofibroma that has not responded to prior treatment. Participants take a daily oral dose for up to 18 cycles. The study aims to see if the dr…

This early-stage study tests a drug called GDC-0084 given alongside radiation therapy for people whose cancer has spread to the brain and has a specific genetic mutation (PI3K). The main goal is to find the safest dose of the drug and see if the combination helps shrink tumors. O…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This early-phase trial tests whether focused ultrasound can temporarily open the blood-brain barrier in children with a rare, aggressive brain tumor called DIPG. The goal is to let the chemotherapy drug doxorubicin reach the tumor more effectively. Only 10 children aged 5 to 18 w…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests whether giving higher doses of focused radiation (stereotactic radiosurgery) to brain tumors is safe and effective, without also radiating the whole brain. About 135 adults with certain types of cancer that have spread to the brain will receive escalating radiati…

This Phase 2 trial tests an experimental chemotherapy drug called berubicin against a standard drug (lomustine) in 252 adults with recurrent glioblastoma, a severe brain cancer. The goal is to see if berubicin can help patients live longer after standard first-line treatment has …

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the brain and spinal cord. The goal is to see how well the drug shrinks these brain tumors. About 41 participants will take lorlatinib o…

This early-stage trial tests a treatment made from a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL). Doctors remove a piece of the tumor, grow the immune cells in a lab, and then infuse them back into the patient to attack the cancer. The study includes 4…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study looks at using a targeted drug called osimertinib together with precise brain radiation as the first treatment for people with a certain type of lung cancer (EGFR-mutant) that has spread to the brain and causes symptoms. Researchers reviewed medical records of 300 pati…

This early-phase trial is testing the safety of an experimental drug called PTC596 (Unesbulin) when given alongside radiation therapy to children and young adults newly diagnosed with diffuse intrinsic pontine glioma (DIPG) or high-grade glioma. The study aims to find the safest …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults with this diagnosis will receive the combination therapy. The main goals are…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This early-stage trial tests the immunotherapy drug pembrolizumab in 60 adults with recurrent glioblastoma, an aggressive brain cancer. The study aims to see how the drug affects immune cells in the tumor and whether it is safe. Participants receive pembrolizumab before and after…

This study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives…

This study tests a new RNA-lipid particle vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma or osteosarcoma that has spread to the lungs. The vaccine is made from the patient's own tumor material and aims to train the immune system to attack the c…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-phase trial tests a new treatment for adults with aggressive brain cancers (glioblastoma, ependymoma, or medulloblastoma) that have spread to the lining of the brain and spinal cord. The treatment uses the patient's own immune cells, modified in a lab to recognize and …

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study tests a new proton therapy machine called PROTEUS® PLUS in 47 adults with solid tumors. The goal is to see if it is safe and effective at controlling cancer. Researchers will measure tumor response and track side effects.

This study follows 160 people who have or will get a CODMAN CERTAS Plus valve, a device implanted in the brain to drain extra fluid. The main goal is to see if the valve is placed correctly and works without problems 30 days after surgery. Participants include children and adults…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This pilot study tests whether an energy-restricted ketogenic diet (ERKD) can help control glioblastoma, an aggressive brain cancer. Sixteen adults with newly diagnosed glioblastoma will follow the diet while receiving standard radiation and chemotherapy. The goal is to see if th…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study compares the safety of routine telephone or video follow-ups versus in-person visits for patients with non-functioning pituitary tumors. Over two years, 812 participants will be randomly assigned to remote or in-person check-ups. The goal is to see if remote follow-up …

This early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. A…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…

This study tests whether adding an experimental drug called indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children wi…

This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This early-stage trial tests a new drug called DM919, alone or with pembrolizumab, in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants receive the drug by …

This early-phase study tests whether a new type of cell therapy, made from a patient's own immune cells that are genetically modified to resist chemotherapy, can be safely given alongside standard chemotherapy for newly diagnosed glioblastoma. About 22 adults with this aggressive…

This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…

This early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…

This study tests a precise type of radiation called proton therapy for people with slow-growing brain tumors (low-grade gliomas). The goal is to see if it can control tumor growth as well as standard radiation while causing fewer side effects by sparing healthy brain tissue. Abou…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This study tests a drug called larotrectinib in children and young adults (up to age 30) with certain cancers that have a specific genetic change called a TRK fusion. The goal is to see if the drug can shrink solid tumors or control leukemia that has returned. The drug works by b…

This clinical trial is testing whether lower doses of radiation and chemotherapy can effectively treat children with medulloblastoma, a type of brain tumor, while reducing long-term side effects. The study includes 360 children aged 3 to 21 years with specific tumor types. Resear…

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the c…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…

This early-phase study tests a new drug called BR115 in 120 people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. Participants receive the drug weekly after an initial two doses, and the study moni…

This early-stage trial tests a new treatment called SC-CAR4BRAIN for children and young adults with certain aggressive brain tumors, including DIPG and DMG. The treatment involves taking a patient's own immune T cells, engineering them in a lab to recognize and attack tumor cells…

This study tests a new drug called MHB039A, a bispecific antibody, in 196 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. Participants receive the drug and are monitored for side effects and t…

This early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main …

This early-stage study tests a new tablet called BB3008 in about 42 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body processes the drug. Participants take the tablet by m…

This study tests a new drug called MHB036C, an antibody-drug conjugate, in 200 adults with advanced solid tumors. The trial has two phases: first to find the safest dose, then to see how well it works. Researchers will monitor side effects and measure drug levels in the blood.

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This early-stage trial tests a single dose of M032, a genetically modified herpes simplex virus that produces IL-12, in 29 patients with recurrent or progressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma). The virus is infused directly into the tumor area…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial explores whether focused ultrasound can enhance the release of tumor DNA into the blood and spinal fluid, potentially making liquid biopsies a more reliable way to diagnose brain tumors. Researchers will use MRI-guided focused ultrasound to partially ablate the tumor i…

This study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive o…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This phase 2 trial tests whether a fluorescent dye called fluorescein can help surgeons identify brain tumor tissue during an operation. About 30 adults with suspected glioma will receive the dye before surgery, and the surgeon will look for glowing areas through a special micros…

This study tests whether a special type of MRI scan can tell the difference between actual tumor growth and harmless treatment-related changes in people who have had surgery for a type of brain cancer called glioma. After treatment, it's often hard to know if a new spot on a scan…

This study compares a new, non-invasive PET-MRI scan to the standard invasive test (IPSS) for finding pituitary tumors in people with Cushing's disease. About 43 adults with confirmed Cushing's will get both tests to see which is more accurate. The goal is to make diagnosis safer…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is testing two different imaging techniques—SPECT and PET—to see how well they can spot brain tumors called gliomas. Forty patients with primary or recurrent glioma will receive injections of two special tracers, then undergo scans to measure how much tracer is taken u…

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This program gave patients with glioma (a type of brain tumor) access to a special imaging agent called 18F-FET. It was used with PET scans to help doctors tell the difference between actual tumor growth and changes caused by previous treatments. The goal was to improve treatment…

This study compares a new ultra-high resolution PET/CT scanner, the NeuroEXPLORER, with standard clinical PET/CT scanners for imaging the head and neck. Researchers aim to see if the new device provides more detailed images to improve diagnosis of conditions like dementia, Parkin…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study tests whether an extra MRI scan, taken later than usual, can better tell the difference between a growing tumor and harmless radiation scar in people with brain metastases who have had radiosurgery. Twenty-five adults with solid tumors (except small cell lung cancer or…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study looked at whether magnetic resonance elastography (MRE), a special type of MRI that measures tissue stiffness, can accurately determine the grade of brain tumors without needing a surgical biopsy. Researchers reviewed data from 626 brain tumor patients to see how well …

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study is testing a new type of PET/MRI scan to see if it can tell the difference between a tumor growing back and radiation damage (called radionecrosis) in people who have had brain radiation for cancer. Both conditions look similar on regular scans, so doctors often need s…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This early-stage trial is testing whether a single low-dose injection of indocyanine green (ICG), a dye already approved for other uses, can help surgeons identify and remove brain or spinal cord tumors more precisely. About 105 adults with nervous system tumors will receive the …

This study tests a new radioactive dye attached to tiny silica particles to improve PET scans for people with melanoma or malignant brain tumors. Ten participants will receive a single injection of the tracer to see how it spreads in the body and how much radiation it gives off. …

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …

This early-phase study is testing whether a special PET scan (68Ga-PSMA-11) can effectively show tumor activity in people with high-grade gliomas or brain metastases. About 11 adults whose tumors are at least 1 cm and who are already scheduled for a biopsy or surgery will receive…

This early-phase study tests a new radioactive tracer called [68Ga]Ga-NOTA-RF for PET scans in 30 people with pituitary tumors. The goal is to see if this tracer can better highlight tumors and help doctors tell different tumor types apart. Participants receive an injection of th…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …

This study aims to see if a simple, inexpensive saliva test can accurately diagnose Cushing's syndrome, a condition where the body makes too much cortisol. Researchers will compare two automated saliva test methods in 380 adults who are already being checked for the condition. Th…

This study compares two different doses of radiation aimed at the head (prophylactic cranial irradiation) to see which is better at preventing brain metastases in people with small cell lung cancer. Participants had their lung cancer diagnosed within the past year and have alread…

Researchers are testing whether a one-day course of targeted radiation works as well as the standard five-day course for people whose cancer has spread to the brain. The trial enrolls about 100 adults with brain metastases and a poor prognosis. Everyone receives precise, image-gu…

This study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study compares two radiation treatments for people whose non-melanoma cancer has spread to the brain with 4 to 15 tumors. One method, stereotactic radiosurgery, delivers a high dose only to the tumors, while the other treats the whole brain. The goal is to see which better c…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study compares three different drugs (dexmedetomidine, fentanyl, and magnesium sulphate) used alongside propofol anesthesia for brain surgery. The goal is to see which combination reduces the amount of propofol needed and improves patient outcomes. 108 adults undergoing elec…

This study tests an online mind-body program designed for people with brain tumors (glioma) and their partners. The program aims to improve spiritual well-being, sleep, mood, and overall quality of life for both. Researchers are enrolling 74 couples to see if the program is pract…

This study tests whether a non-invasive technique called navigated repetitive transcranial magnetic stimulation (nrTMS) can help people with brain tumors recover movement after surgery. About 32 patients who recently had surgery for a brain tumor near the movement-control area of…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study tests a program called ENABLE Cornerstone, where specially trained lay coaches provide support to family caregivers of people with advanced cancer. The coaches help caregivers manage stress, improve coping skills, and plan for the future through phone or in-person sess…

This pilot trial is testing how to safely give a second round of radiation to people whose brain tumors have returned after previous radiation. The study uses special dose limits and the drug bevacizumab to try to reduce brain damage. Forty participants are being followed to see …

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study tests a modified whole brain radiation technique that avoids a specific area of the brain called the corpus callosum genu, which is important for memory and thinking. The goal is to see if this approach helps preserve cognitive function in people with brain metastases …

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study explores whether a supervised, circuit-based resistance training program can help glioblastoma patients maintain muscle mass and perform daily tasks more easily. Researchers will enroll 24 adults with glioblastoma who are currently on treatment. Participants will exerc…

This trial planned to compare a second round of whole brain radiotherapy plus supportive care against supportive care alone for people with brain metastases that returned after initial treatment. It was designed for patients who could not have surgery or precise radiation. Howeve…

This early-phase study tests giving a precise dose of radiation to brain tumors before surgical removal, rather than after. The goal is to protect healthy brain tissue and possibly eliminate the need for additional radiation after surgery. About 25 adults with brain metastases (t…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study looks at whether a ketogenic (high-fat, low-carb) diet is practical and beneficial for 24 adults with brain metastases who are scheduled for radiosurgery. Participants will follow either a ketogenic diet or a standard healthy diet for 16 weeks. Researchers will track d…

This study tests a brain training method called neurofeedback, combined with cognitive exercises, to help children aged 6-18 who had a brain tumor and now have trouble with attention or memory. Half of the 50 participants get real neurofeedback, the other half a sham version, and…

This study tests whether early visits with a brain health specialist can help people with cancer that has spread to the brain maintain their quality of life after radiation therapy. About 110 adults with solid tumors and brain metastases will receive neuropsychological care along…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at how precise radiation (stereotactic radiosurgery) affects memory and thinking in people with 6 or more brain tumors that have spread from other cancers. About 80 adults will take part to find the safest radiation dose and measure any decline in memory over 4 m…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study follows 110 people with brain metastases who are receiving either focused or whole-brain radiation. Researchers use advanced MRI scans and memory tests before treatment and for two years after to see if the scans can predict thinking and memory problems. The goal is to…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study investigates whether the emotional distress of parents—such as depression, anxiety, or trauma—affects how well children with recurrent medulloblastoma follow their treatment plans. Researchers will follow 450 parent-child pairs across four hospitals, measuring parental…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study tests whether a non-invasive brain-mapping tool called nTMS can help doctors plan radiation treatment for brain tumors near the motor cortex—the area that controls movement. About 22 adults who already had radiation for brain tumors will undergo nTMS to see if it provi…

This study looks at how people with both cancer and heart failure feel day-to-day. Researchers will ask 100 participants about their symptoms and quality of life using simple questionnaires. No new treatments are tested—the goal is to better understand the challenges these patien…

This study follows children and young adults (up to age 35) with brain or skull base tumors who are scheduled to receive radiation therapy to the brain. Researchers use brain scans to track changes in brain structure and volume over time. They also measure thinking skills, hormon…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study was designed to look back at the health of people with Cushing's disease in Western France between 1990 and 2015. The goal was to find out how many patients went into remission and how many had their disease come back after their first surgery. However, the study was w…

This study investigates how the brain processes speech sounds to understand language. Researchers will record brain activity from people with epilepsy or brain tumors who already have electrodes implanted for medical reasons. Participants listen to short speech sounds while their…

This study follows over 1,500 young adult survivors of childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma to see how frailty—a measure of physical weakness and vulnerability—changes over five years. Researchers want to know if frailty can predict future chronic h…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study collects multiple samples from different parts of a glioblastoma tumor during surgery. Researchers will analyze the samples to learn how genetic changes vary within a single tumor. The goal is to improve future diagnosis and treatment of brain tumors. The study involve…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study follows 400 patients for two years after they have endoscopic endonasal skull base surgery (surgery through the nose to reach the base of the skull). The goal is to measure their quality of life and nose function using standard questionnaires. It does not test a new tr…

This study follows 75 adults with benign or slow-growing brain tumors who are receiving partial brain radiation. Researchers will use memory tests and MRI scans before treatment and at 6 and 12 months after to see how radiation affects thinking and memory. The goal is to identify…

This study follows 600 children and young adults (ages 2-25) who received radiation therapy for brain tumors or other cancers. Researchers want to understand how treatment affects their quality of life over time, including both positive and negative effects. The goal is to use th…

This study tests a new ultrasound system (SonoClear®) that uses a special gel to mimic brain tissue, aiming to give surgeons clearer images during brain tumor removal. Fifteen adults with glioma (a type of brain tumor) are participating. The main goal is to see if the new system …

This study follows 71 glioma patients before and after radiation therapy to see how their thinking skills change. Researchers use special brain scans (RS-fMRI) to map which brain networks are most harmed by radiation. The goal is to learn which areas to avoid during treatment pla…

This study looks at how the location of a tumor in the cerebellum (the part of the brain that controls balance and coordination) affects a person's thinking and movement skills before and after surgery. Researchers will follow 66 adults with brain tumors, testing their cognition …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study tracks 80 patients with brain tumors (metastases or meningiomas) who receive stereotactic radiosurgery. Researchers use memory tests and quality-of-life questionnaires before treatment and every 3 months for a year to see if and how brain function changes. By comparing…

This phase 1 study tests a new PET imaging tracer called 89Zr-cRGDY in 17 people with malignant brain tumors or pituitary adenomas. The tracer is given in a very small dose to see how it spreads and clears from the body. The goal is to improve brain tumor imaging, not to treat th…

This pilot study aimed to see if a diet low in two specific nutrients (cysteine and methionine) could affect metabolism in patients with recurrent gliomas. Up to 30 participants were to be randomly assigned to either a normal diet or the special diet for 2, 4, or 7 days before st…

This study uses a special PET scan to measure brain inflammation in children with medulloblastoma who receive whole-brain radiation. Twenty-two participants will be scanned four times over two years to see how inflammation changes. The goal is to understand how radiation affects …

This study looks at two types of radiation for people with 5 to 30 brain tumors that have spread from other cancers. One group gets focused radiation (SRS) alone, the other gets whole-brain radiation plus SRS. The main goal is to see which approach better protects memory and thin…

This study looks at two different blood pressure goals for adults who just had brain tumor surgery. Half the patients will have a target of less than 160 mmHg, the other half less than 140 mmHg. Researchers want to see which group leaves the hospital sooner, without more bleeding…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study is observing 328 adults who receive a Neuro-Patch during brain or spine surgery to repair the protective lining around the brain or spinal cord. Researchers are tracking complications and how easy the patch is for surgeons to use. The goal is to gather real-world data …

This study looks at how doctors, patients with glioblastoma (a serious brain cancer), and their caregivers talk about the disease, scan results, and treatment choices. Researchers will use surveys and tests to understand these conversations. The goal is to find ways to improve co…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …

This study follows 1500 patients with pituitary gland disorders to see how they fare over time, whether treated with medication, surgery, or just monitoring. Researchers will track tumor regrowth after surgery to find clues that predict recurrence. The goal is to learn, not to te…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study looks at 500 adults having pituitary tumor surgery through the nose. Researchers want to find out who gets headaches soon after surgery and build a tool to predict that risk. Participants report their pain daily and fill out surveys for up to 3 months after surgery.

This study looks at how proton beam radiation affects brain networks and thinking in children and young adults (ages 6-25) treated for brain tumors. Researchers will use special MRI scans taken at rest, along with thinking tests and quality-of-life questionnaires, to compare pati…

This study aims to develop a new way to measure arm and hand function in people with brain disorders like stroke or Parkinson's disease. Researchers will use a smart board and smart glove to collect movement data and compare it with standard tests. The goal is to create a more pr…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…

This study surveys 530 prolactinoma patients and their doctors to understand real-world treatment experiences, side effects, and preferences. The goal is to identify gaps in care and guide future research for better, more personalized treatment strategies. No new treatments are t…

This study looks at how brain tumors change the way different parts of the brain connect and communicate. Researchers will use brain scans and electrical recordings from 30 adults scheduled for tumor removal surgery. The goal is to better understand brain plasticity and improve f…

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study was designed to see if a special MRI technique could help surgeons map important brain pathways in people with malignant brain tumors. It was withdrawn before any participants were enrolled, so no data or results were collected. The goal was to compare the MRI findings…

This study is a large registry that collects information from children diagnosed with cancer across the US and Canada. Its goal is to help researchers understand patterns, causes, and characteristics of childhood cancer. No treatments or drugs are given—it is purely for research …

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study was designed to see if a special MRI technique, using extra oxygen, could create maps of low-oxygen areas in brain tumors. Low oxygen can make tumors grow and resist treatment. The goal was to help doctors plan more personalized therapies. However, the study was withdr…

This study tests whether adding a weekly check-in with a radiology technician (called a MERM) to standard doctor visits can better detect side effects in brain tumor patients receiving proton therapy. About 92 adults with brain or upper airway tumors will be randomly assigned to …

This study compares two anesthetic drugs, fentanyl and ketamine, to see which one better helps surgeons find seizure-causing brain tissue during epilepsy surgery in children. Eighty-eight children aged 2-18 with brain tumors and epilepsy will receive one of the drugs during surge…

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…